Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Ann Oncol · 2011 · PMC3003616 · PMID 20643862

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The trial met its primary end point, demonstrating significantly superior PFS with the combination confirmed by both independent radiology and independent oncology reviews, and with a positive trend in the interim analysis of OS [ 7 , 8 ].

also in 11,005 other papers

a favorable trendno p-value reported

updated survival analysis in the overall population The updated interim analysis of survival, with 419 death events (38% censored data) and an additional year of follow-up, continues to show a favorable trend for trabectedin/PLD arm, with an identical 15% reduction in the risk of death than that shown 1 year earlier [ 8 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.